A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency

Recruiting now · Phase 2

Conditions studied: Congenital Factor VII Deficiency

In brief

Open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of sutacimig monotherapy in participants with congenital FVII deficiency (FVIID).

Key facts

Study ID
NCT07347249
Run by
Hemab ApS
People needed
18
Starts
2026-03-11
Expected to finish
2027-11-01
Last updated by the study team
2026-07-22

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.